Drug
Bnt162b1
Bnt162b1: highest development phase Phase 2/3, developed by BioNTech. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| BNT162b1 NCT04368728 | Phase 2/3 | SARS-CoV-2 Infection |
Latest
No recent events.
Follow Bnt162b1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.